Bluejay Diagnostics, Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Bluejay Diagnostics, Inc. (BJDX) reported Federal Income Tax Expense (Benefit), Continuing Operations of $16.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2024-03-28
- Bluejay Diagnostics, Inc. federal income tax expense (benefit), continuing operations for fiscal 2023 was $16.80M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2023-12-31 | $16.80M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |